methodology, findings from the studies were found to be highly variable-total costs ranged between USD 3,000 to 12,000, while proportion of indirect costs varied between 32 and 82% across these studies. Based on collected information, direct costs attributed to medical care contributed to only 20% while informal care provided by family and direct costs of social care (provided by community care professionals, and in residential home settings) contributed 40% each of the total cost of dementia in China. ConClusions: Costs data for Dementia in China is limited and further efforts are required to generate this data to support health policy and research as changing demographics, urban/rural shift and increased diagnosis rates are expected to lead to an epidemic of AD dementia in China in the near future. PMH20 EconoMic BurdEn of AutisM And AutisM-rElAtEd sPEctruM disordErs (Asd) in Eu5 countriEs
A885fewer relapses(0.24) than those on oral(0.29~0.43) or no treatment. The reduction in relapse was due to improved treatment persistence and better efficacy. Receiving either PP1M
stringent parameters. These results corroborate national publications reporting the poor level of control in Brazilian patients with T2DM and demonstrate opportunities to improve overall knowledge and achieve better diabetes-related outcomes. Further work should quantify the clinical and economic burden when diabetes-related CQM measures are unmet.
Objectives: The ACTG 5257 clinical trial showed that raltegravir (RAL) was superior to atazanavir/ritonavir (ATV/r) and darunavir/ritonavir (DRV/r), when used in combination with tenofovir DF/emtricitabine (TDF/FTC), in a 96-week composite endpoint combining virologic efficacy and tolerability for treatment-naive adults with HIV-1 infection. This study aimed to estimate costs and efficiency associated with these three regimens in Spain. MethOds: An economic model was developed to estimate costs for antiretroviral drugs, adverse event management, and HIV care for individuals initiating first-line therapy. Head-to-head efficacy and safety data (discontinuation rates based on the trial's composite endpoint, mean CD4+ cell-count changes, adverse event incidence) up to 96 weeks for RAL, ATV/r, and DRV/r were obtained from the ACTG 5257 clinical trial. Antiretroviral drug costs were based on hospital costs with additional mandatory discounts applied. Adverse event management costs and HIV care costs, stratified by CD4+ cell-count range, were obtained from published sources and inflated to 2015 euros. Costs per successfully treated patient (i.e., remaining on first-line therapy for 96 weeks) were estimated for the three regimens and tested in sensitivity and scenario analyses. All outcomes were discounted at 3.0% per year. Results: At 96 weeks, RAL was associated with higher antiretroviral drug costs, lower adverse event costs, and similar HIV care costs when compared with either ATV/r or DRV/r. Total costs per successfully treated patient were € 22,377 for RAL, € 26,629 for ATV/r, and € 23,928 for DRV/r. These results were found to be robust in probabilistic sensitivity and scenario analyses. cOnclusiOns: RAL has the lowest cost per successfully treated patient when compared with two other common first-line regimens, DRV/r and ATV/r, each used in combination with TDF/FTC, for treatment-naive adults with HIV-1 infection in Spain. This economic evidence further complements the known clinical benefits of RAL as reported in the ACTG 5257 clinical trial.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.